CG
INO icon

Cutler Group’s Inovio Pharmaceuticals INO Stock Holding History

Cutler Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-250
Closed -$2K – 6002
2021
Q2 		$2K Buy
250
+25
+11% +$2.4K ﹤0.01% 5013
2021
Q1 		$4K Sell
225
-125
-36% -$16.4K ﹤0.01% 4515
2020
Q4 		$4K Sell
350
-1,900
-84% -$253K ﹤0.01% 3790
2020
Q3 		$40K Sell
2,250
-7,867
-78% -$1.64M ﹤0.01% 1938
2020
Q2 		$886K Sell
10,117
-13,050
-56% -$2.1M 0.06% 323
2020
Q1 		$369K Buy
+23,167
New +$1.43M 0.02% 666
2017
Q4 		– Sell
-2,158
Closed -$6K – 5354
2017
Q3 		$6K Buy
2,158
+1,375
+176% +$102K ﹤0.01% 4222
2017
Q2 		$3K Sell
783
-459
-37% -$39.3K ﹤0.01% 5245
2017
Q1 		$2K Sell
1,242
-4,241
-77% -$338K ﹤0.01% 5449
2016
Q4 		$4K Buy
5,483
+2,558
+87% +$231K ﹤0.01% 5081
2016
Q3 		$35K Sell
2,925
-6,292
-68% -$695K ﹤0.01% 2820
2016
Q2 		$88K Buy
9,217
+3,200
+53% +$389K ﹤0.01% 1804
2016
Q1 		$101K Buy
6,017
+4,084
+211% +$315K 0.01% 1609
2015
Q4 		$4K Buy
+1,933
New +$154K ﹤0.01% 5073

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cutler Group's INO Position: Q1 2023 in Review

Cutler Group sold out of Inovio Pharmaceuticals (INO) in Q1 2023, closing a stake of 58 shares — an estimated $1K sold.

Cutler Group first reported a position in INO in Q4 2015 and held it in 21 quarters. The position peaked at $189K in Q4 2021. 174 funds tracked by Wall St. Rank hold INO as of Q1 2023.

  • Cutler Group reported no remaining Inovio Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 58 Inovio Pharmaceuticals shares in Q1 2023, an estimated $1K.
  • Cutler Group first reported a position in Inovio Pharmaceuticals in Q4 2015 and held it in 21 quarters.
  • Cutler Group's Inovio Pharmaceuticals position peaked at $189K in Q4 2021.
  • 174 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.